Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone ophthalmic - AbbVie

Drug Profile

Dexamethasone ophthalmic - AbbVie

Alternative Names: DEX implant; DEX PS DDS; Dexamethasone implant; Dexamethasone posterior segment drug delivery system; Ozurdex; Posurdex; SK-0503

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie; Allergan; Sanwa Kagaku Kenkyusho
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema; Retinal oedema; Uveitis
  • No development reported Age-related macular degeneration

Most Recent Events

  • 26 Jul 2021 Allergan initiated phase III trials for Diabetic macular oedema (Intravitreous, Implant) in October 2021 (NCT04976777)
  • 16 Apr 2021 No development reported - Phase-II for Diabetic macular oedema (Combination therapy) in USA (Intravitreous) (Allergan pipeline, April 2021))
  • 16 Apr 2021 No development reported - Phase-II/III for Retinal oedema in Japan (Ophthalmic) (JapicCTI-101194) (Allergan pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top